Kotak Institutional Equities has struck a bullish note on Piramal Pharma with its latest research, reiterating a BUY recommendation and projecting a fair value of Rs305 per share against a current
Motilal Oswal has reiterated its BUY rating on Glenmark Pharmaceuticals, setting a compelling price target of Rs 2,430—implying a robust 28% upside from current levels.
Glenmark Pharmaceuticals has seized the spotlight within India’s pharmaceutical landscape, propelled by a record-breaking global licensing agreement for its flagship oncology asset.
Morningstar has issued a BUY recommendation on CRISPR Therapeutics AG (NASDAQ: CRSP), underscoring the stock’s significant undervaluation and robust long-term prospects, in its latest research repo
Kotak Institutional Equities has issued a BUY recommendation for Syngene International, setting a fair value target of Rs 825 per share, a significant upside from its current market price of Rs 633
